SABS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SABS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
SAB Biotherapeutics's Capital Expenditure for the three months ended in Dec. 2023 was $-0.07 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-13.45 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for SAB Biotherapeutics's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Capex-to-Operating-Cash-Flow | - | 1.27 | 5.51 | - | - |
SAB Biotherapeutics Quarterly Data | |||||||||||||||
Dec19 | Jun20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, SAB Biotherapeutics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's Capex-to-Operating-Cash-Flow falls into.
SAB Biotherapeutics's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.197) | / | -25.119 | |
= | N/A |
SAB Biotherapeutics's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.068) | / | -13.447 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics (NAS:SABS) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of SAB Biotherapeutics's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Eddie Joe Sullivan | director, 10 percent owner, officer: Chief Executive Officer | 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104 |
Michael King | officer: CHIEF FINANCIAL OFFICER | 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104 |
Samuel J Reich | director, officer: Executive Chairman | ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104 |
Sessa Capital Im, L.p. | director | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Andrew Moin | director | 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104 |
Sessa Capital (master), L.p. | director | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Sessa Capital Im Gp, Llc | director | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
John Petry | director | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Sessa Capital Gp, Llc | director | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Erick Lucera | director | 138 THISTLE ROAD, NORTH ANDOVER MA 08145 |
David Charles Link | director | 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104 |
Christine E Hamilton | director, 10 percent owner | 225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117 |
Scott Giberson | director | 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104 |
Alexandra Kropotova | officer: Chief Medical Officer | RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807 |
Jeffrey G Spragens | director | 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137 |
From GuruFocus
By Marketwired • 06-21-2023
By Value_Insider Value_Insider • 11-15-2022
By Marketwired • 10-19-2023
By Marketwired • 10-05-2023
By sperokesalga sperokesalga • 04-18-2023
By Value_Insider Value_Insider • 12-07-2022
By Value_Insider Value_Insider • 11-21-2022
By GlobeNewswire GlobeNewswire • 03-31-2023
By Stock market mentor Stock market mentor • 01-19-2023
By Marketwired • 08-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.